FDA Listing for Biosimilars: How They Are Rated and Approved

Have you ever wondered why a "generic" version of a complex drug isn't called a generic? Or why your doctor might hesitate to switch you from one biologic medication to another that looks identical on paper? The answer lies in how the U.S. Food and Drug Administration (FDA) evaluates these products. Unlike simple chemical drugs, biosimilars are biological medical products that are highly similar to an already approved reference biologic product. They are not rated with stars or letters. Instead, they undergo a rigorous scientific evaluation to prove they are essentially the same as the original drug.

If you are navigating the world of biologics-whether as a patient, a healthcare provider, or someone interested in pharmaceutical economics-understanding this process is crucial. It explains why costs drop, why some drugs can be switched automatically at the pharmacy, and why others require a doctor's specific order. Let’s break down exactly how the FDA determines if a biosimilar is good enough to join the market.

The Core Concept: Biosimilarity, Not Identity

To understand the rating process, we first need to distinguish between generics and biosimilars. A generic drug is a carbon copy of a small-molecule chemical drug. Think of aspirin; it is made in a lab using precise chemical formulas, so every molecule is identical. You can make more of it without worrying about slight variations.

Biosimilars are different. They are produced by living cells-like bacteria, yeast, or mammalian cells. Because they come from life, there is always some natural variation. No two batches of a biologic are exactly identical, even from the same manufacturer. Therefore, the FDA does not look for identity. They look for similarity.

The legal standard, established by the Biologics Price Competition and Innovation Act (BPCIA) of 2009, requires that a biosimilar be "highly similar" to the reference product, with "no clinically meaningful differences" in safety, purity, and potency. This is the golden rule. If a product meets this standard, it gets approved. If it doesn’t, it goes back to the drawing board.

The Stepwise Evaluation Process

The FDA uses a "totality of evidence" approach. This means they don't rely on just one test. They build a case step-by-step, starting with the most detailed scientific analysis and moving toward human testing only if necessary. Here is how the ladder works:

1. Analytical Studies (The Foundation): This is the most critical step. Manufacturers must use state-of-the-art techniques to characterize the molecular structure, purity, and biological activity of both the biosimilar and the reference product. The FDA evaluates up to 300 critical quality attributes. For many attributes, the similarity threshold is extremely high, often requiring 95-99% analytical similarity. If the molecules look almost identical under the microscope and in chemical assays, the FDA may skip later steps.
2. Animal Studies: If the analytical data shows high similarity, animal studies might be waived. However, if there are minor differences, the FDA may require toxicity assessments in relevant species to ensure no unexpected reactions occur in living organisms.
3. Pharmacokinetic and Pharmacodynamic (PK/PD) Studies: These studies are conducted in humans (healthy volunteers or patients). They measure how the body absorbs, distributes, metabolizes, and excretes the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics). A standard design involves 50-100 participants per arm. The goal is to show that the biosimilar behaves in the body just like the reference product.
4. Clinical Efficacy Studies: Historically, large clinical trials were required. However, recent guidance updates (September 2024) allow manufacturers to potentially eliminate these comparative efficacy studies if the analytical and PK/PD data are strong enough. This is a significant shift that saves time and money while maintaining safety standards.
5. Immunogenicity Assessment: This is mandatory for all biosimilars. Since biologics are proteins, the immune system might recognize them as foreign invaders. Manufacturers must run assays over 24-52 weeks to check if the biosimilar triggers an immune response different from the reference product.

The Purple Book: Where Biosimilars Get Listed

Once a biosimilar passes all these hurdles, it needs a place to live publicly. That place is the Purple Book, which is the official FDA listing of all approved biologics, including reference products and biosimilars. As of late 2025, this database contains hundreds of reference biologics and dozens of approved biosimilars.

The Purple Book is more than just a list. It includes critical information such as:

• Licensure dates
• Patent information (mandatory since June 2021)
• Exclusivity periods
• Interchangeability status

This transparency helps doctors, pharmacists, and payers understand the legal and clinical landscape. For example, if a patent dispute is ongoing, it will be reflected here, which affects whether a biosimilar can actually be sold yet, even if it is approved.

Interchangeability: The Higher Bar

Not all biosimilars are created equal in terms of substitution rules. Some receive a special designation: interchangeable. This is a higher standard set by the FDA. To earn this label, a biosimilar must meet all the requirements for biosimilarity plus provide additional data demonstrating that:

• It can be expected to produce the same clinical result as the reference product in any given patient.
• Any risk in switching between the biosimilar and the reference product is not greater than the risk of switching between different lots of the reference product itself.

As of October 2025, only 17 products have achieved interchangeable status. Why so few? Because proving interchangeability requires extra studies, often involving multiple switches between the biosimilar and the reference drug in patients. This adds cost and complexity. However, for states that allow automatic substitution at the pharmacy (similar to generics), this designation is key to getting the drug into patients' hands quickly.

Why the FDA Process Is Considered Stringent

You might hear people say the FDA is tough on biosimilars compared to other agencies. There is truth to this. Dr. Steven Kozlowski, former Director of the Office of Biotechnology Products at the FDA, noted in 2023 that the FDA requires more comprehensive analytical characterization than the European Medicines Agency (EMA).

Here are some hard numbers that illustrate this difference:

• Approval Rates: Europe has approved 118 biosimilars as of 2025, while the U.S. has approved 43.
• Time to Approval: The median time from submission to approval in the U.S. is 3.2 years, compared to 2.1 years in the EU.
• Cost: Analytical characterization alone can cost $120-180 million, accounting for 30-40% of total development costs.

Is this stricter approach better? Patient advocacy groups argue yes. The Cancer Support Community praised the FDA’s rigor, noting that in nine years of post-marketing surveillance, there have been no biosimilar-specific safety signals. Real-world data from the FDA’s Sentinel Initiative shows adverse event rates for biosimilars (0.8 per 10,000 patients) are statistically equivalent to reference products (0.7 per 10,000 patients). The strictness buys confidence.

Recent Changes and Future Outlook

The landscape is shifting. In September 2024, the FDA finalized updated guidance that allows manufacturers to skip comparative efficacy studies in certain cases. This change is expected to save developers $50-100 million per product and cut development timelines by 12-18 months. Additionally, a June 2025 policy change allows for extrapolation of indications based solely on robust analytical data for well-characterized proteins.

These changes aim to address the barriers identified in the FDA’s Biosimilars Action Plan, such as complex manufacturing costs and patent litigation delays. The goal is clear: increase access to affordable biologics without compromising safety. By 2030, the FDA projects biosimilars could reach 30% of the biologics market, generating billions in savings.

However, challenges remain. Complex molecules like antibody-drug conjugates still lack clear guidance. Only three applications for these complex biosimilars have been submitted, with none approved yet. The FDA is working on new guidelines for these advanced products, targeting release by Q3 2026.

What This Means for You

If you are a patient prescribed a biologic, ask your doctor if a biosimilar is available. It could mean lower out-of-pocket costs. If you are a provider, check the Purple Book for interchangeability status to know if you can let the pharmacist handle the substitution. And if you are an investor or industry professional, watch the FDA’s roadmap for AI tools in review and new guidance on complex molecules. The biosimilar market is growing, but it is evolving fast.